Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences [Yahoo! Finance]
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences